Inventiva S.A.
lanifibranor
metabolic dysfunction-associated steatohepatitis (MASH)
Countdown
358days
Catalyst readout · ~ Jun 30, 2027 estimated
What's at stake
A key catalyst for lanifibranor (metabolic dysfunction-associated steatohepatitis (MASH)) is expected ~ Jun 30, 2027.
Primary source
· SEC 6-K
verified 13h ago
“anticipated regulatory filing in the first half of 2027”